Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.

Investigational new drugs - 1 Jun 2008

Gounder Murugesan K, Nazar Ahamed S, Saleem Ahamed, Pungaliya Pooja, Kulkarni Diptee, Versace Richard, Rubin Eric H

Abstract excerpt

Clinically relevant resistance to the currently approved camptothecins, irinotecan and topotecan, is poorly understood but may involve increased expression of ATP-dependent drug transporters such as ABCG2 (breast cancer resistant protein, BCRP). Gimatecan (ST1481) is a lipophilic 7-substituted camptothecin derivative that exhibits potent anti-tumor activity in a variety of preclinical cancer models and is under...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Topoisomerases, Type I

Share to Drug Resistance, Neoplasm

Share to Irinotecan

Share to Multidrug Resistance-Associated Protein 2

Share to Multidrug Resistance-Associated Proteins

Source

Identifiers

PMID: 17943230
DOI: 10.1007/s10637-007-9093-0

Genes

ABCG2
ABCC4
ABCB1
ABCC1
ABCC2
TOP1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.PMID 17943230Read ↗

Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin AnaloguesSemantic proximity Read ↗

Mechanisms of Cellular Resistance to CamptothecinsSemantic proximity Read ↗

The Current Status of Camptothecin Analogues as Antitumor AgentsSemantic proximity Read ↗

Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid.Semantic proximity Read ↗

Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.Semantic proximity Read ↗

Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.Semantic proximity Read ↗

Current Status and Perspectives in the Development of CamptothecinsSemantic proximity Read ↗

FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistanceSemantic proximity Read ↗

Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.Semantic proximity Read ↗

Differential effects of mitomycin C and doxorubicin on P-glycoprotein expressionSemantic proximity Read ↗

Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A ReviewSemantic proximity Read ↗

Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.